Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1992 1
1994 2
1995 1
1996 3
1997 1
2000 1
2004 4
2005 3
2006 3
2007 2
2008 3
2009 4
2010 4
2011 7
2012 7
2013 4
2014 1
2015 5
2016 7
2017 4
2018 5
2019 9
2020 3
2021 3
2022 2
2023 2

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23775611

82 results

Results by year

Filters applied: . Clear all
Page 1
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM. Mora S, et al. J Am Coll Cardiol. 2012 Apr 24;59(17):1521-8. doi: 10.1016/j.jacc.2011.12.035. J Am Coll Cardiol. 2012. PMID: 22516441 Free PMC article.
Association between Vitamin D and Circulating Lipids in Early Childhood.
Birken CS, Lebovic G, Anderson LN, McCrindle BW, Mamdani M, Kandasamy S, Khovratovich M, Parkin PC, Maguire JL; TARGet Kids! collaboration. Birken CS, et al. PLoS One. 2015 Jul 15;10(7):e0131938. doi: 10.1371/journal.pone.0131938. eCollection 2015. PLoS One. 2015. PMID: 26176958 Free PMC article.
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Pasternak RC, et al. Ann Intern Med. 1996 Oct 1;125(7):529-40. doi: 10.7326/0003-4819-125-7-199610010-00001. Ann Intern Med. 1996. PMID: 8815751 Clinical Trial.
82 results